AudioScholar Oncology Weekly

AudioScholar
  • 0.0 (0)
  • Medicine
  • Weekly

Oncology — a weekly podcast briefing of the most significant peer-reviewed oncology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

  1. 4d ago

    This Week in Oncology — Oct 28, 2026

    Editor's Pick: Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new targeted and immune strategies in lung cancer, immunotherapy for mismatch repair-deficient colorectal cancer, and antibody-drug conjugates moving into earlier l… This week's papers: 1. Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. — New England Journal of Medicine 2026 2. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. — New England Journal of Medicine 2026 3. Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. — New England Journal of Medicine 2026 4. Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-… — The Lancet 2026 5. Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial. — Annals of Oncology 2026 6. Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal… — Annals of Oncology 2026 7. 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, rand… — The Lancet 2026 8. Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. — New England Journal of Medicine 2026 9. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. — JAMA 2026 10. Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer. — New England Journal of Medicine 2026 Listen at https://audioscholar.cc/episode/esntzj8j3z

  2. Oct 21

    This Week in Oncology — Oct 21, 2026

    Editor's Pick: Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning chemotherapy-free and transplant-sparing strategies in blood cancers, de-escalation and refinement in early breast cancer, and the expanding, sometimes sobering, re… This week's papers: 1. Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. — New England Journal of Medicine 2026 2. First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Maligna… — Journal of Clinical Oncology 2026 3. Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IM… — Journal of Clinical Oncology 2026 4. Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 ra… — Annals of Oncology 2026 5. DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer. — Clinical Cancer Research 2026 6. Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations. — Cancer Cell 2026 7. Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study. — Journal of Clinical Oncology 2026 8. Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0. — Journal of Clinical Oncology 2026 9. Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial. — Nature Medicine 2026 10. Nivolumab-Ipilimumab for Localized Microsatellite Instability-High Gastric/Gastroesophageal Junction Adenocarcinoma: The Phase 2 NEONIPIGA Nonrandomized Clinic… — JAMA Oncology 2026 Listen at https://audioscholar.cc/episode/qycvs4rbnr

  3. Oct 14

    This Week in Oncology — Oct 14, 2026

    Editor's Pick: Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505) (Journal of Clinical Oncology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning breast cancer radiation, ablation and screening, the reach of germline testing, and a wave of novel targeted agents across gynaecologic, genitourinary and rarer tum… This week's papers: 1. Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). — Journal of Clinical Oncology 2026 2. NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. — Journal of Clinical Oncology 2026 3. Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month f… — The Lancet Oncology 2026 4. Universal Germline Genetic Testing after a Diagnosis of Cancer. — Cancer Discovery 2026 5. Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, singl… — The Lancet Oncology 2026 6. Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. — Annals of Oncology 2026 7. Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial. — JAMA Oncology 2026 8. Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer. — Journal of Clinical Oncology 2026 9. VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. — Journal of Clinical Oncology 2026 10. RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial. — Journal of Clinical Oncology 2026 Listen at https://audioscholar.cc/episode/swnfuv2tsd

  4. Oct 7

    This Week in Oncology — Oct 7, 2026

    Editor's Pick: Giredestrant plus Everolimus in Advanced Breast Cancer (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new ways to overcome treatment resistance in breast and pancreatic cancer, the growing role of immunotherapy before surgery and transplant, advances in hematologic… This week's papers: 1. Giredestrant plus Everolimus in Advanced Breast Cancer. — New England Journal of Medicine 2026 2. Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More. — Clinical Cancer Research 2026 3. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. — Nature Medicine 2026 4. Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). — Nature Medicine 2026 5. Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma. — JAMA Oncology 2026 6. FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma. — Clinical Cancer Research 2026 7. Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial. — Journal of Clinical Oncology 2026 8. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.3. — Journal of Clinical Oncology 2026 9. Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening: A Randomized Clinical Trial. — JAMA 2026 10. Efficacy of Cryotherapy in Preventing Taxane-Induced Neuropathy: The CryoPac Randomised Controlled Trial. — Annals of Oncology 2026 Listen at https://audioscholar.cc/episode/cmwb8zy94d

  5. Sep 30

    This Week in Oncology — Sep 30, 2026

    Editor's Pick: Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial (The Lancet Oncology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning local therapy de-escalation and delivery in breast and brain disease, immunotherapy biomarkers and combinations, and a set of population-level studies on prevention… This week's papers: 1. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a… — The Lancet Oncology 2026 2. Surgery and tile-based radiation therapy versus surgery and stereotactic radiation for newly diagnosed brain metastases (ROADS): a randomized, open-label, phas… — Journal of Clinical Oncology 2026 3. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer. — Journal of Clinical Oncology 2026 4. Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the ph… — Annals of Oncology 2026 5. Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. — Clinical Cancer Research 2026 6. Selective serotonin reuptake inhibitors and immune checkpoint blockade in solid tumors: A target trial emulation with pan-cancer transcriptomic analyses. — PLOS Medicine 2026 7. Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis. — The Lancet Oncology 2026 8. Prostate Cancer Screening and Likelihood of Benefit in Veterans Affairs and Fee-for-Service Medicare. — JAMA Internal Medicine 2026 9. Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial. — Journal of Clinical Oncology 2026 10. Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the E… — The Lancet Oncology 2026 Listen at https://audioscholar.cc/episode/maee6de3gc

  6. Sep 23

    This Week in Oncology — Sep 23, 2026

    Editor's Pick: Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study (Journal of Clinical Oncology, 2026) Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning first-line advances and immune biology in thoracic cancers, a run of breast cancer studies that challenge how we operate and how we combine targeted agents, and a b… This week's papers: 1. Phase III Trials Test First-Line Options in Advanced NSCLC. — Cancer Discovery 2026 2. Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer. — Annals of Oncology 2026 3. Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special St… — Journal of Clinical Oncology 2026 4. Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study. — Clinical Cancer Research 2026 5. Vaccines for Cancer: A Translational Science Review. — JAMA 2026 6. Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi. — Journal of Clinical Oncology 2026 7. Precision prevention and early detection: framework for a new clinical cancer control pathway. — The Lancet 2026 8. γδ T cells modulate anti-tumor immunity in small cell lung cancer. — Cancer Cell 2026 9. Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma. — Nature Medicine 2026 10. Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care. — Journal of Clinical Oncology 2026 Listen at https://audioscholar.cc/episode/636a8quyhc

  7. Sep 16

    This Week in Oncology — Sep 16, 2026

    Editor's Pick: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy (New England Journal of Medicine, 2026) Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning a wave of new antibody-based drugs in lung, breast and head and neck cancer, circulating tumour DNA and artificial intelligence as tools for risk stratification, an… This week's papers: 1. Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy. — New England Journal of Medicine 2026 2. Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanc… — Annals of Oncology 2026 3. Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study. — Clinical Cancer Research 2026 4. P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape. — Journal of Clinical Oncology 2026 5. Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial. — Nature Cancer 2026 6. Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study. — Journal of Clinical Oncology 2026 7. Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC. — Nature Medicine 2026 8. Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cl… — The Lancet Oncology 2026 9. Effective Palliative Care for Hospice Transitions. — JAMA Internal Medicine 2026 10. Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments. — Journal of Clinical Oncology 2026 Listen at https://audioscholar.cc/episode/rpesgatmfy

  8. Sep 9

    This Week in Oncology — Sep 9, 2026

    Editor's Pick: An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial (The Lancet Oncology, 2026) Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning targeted therapy in thoracic cancers, precision-guided treatment selection across molecularly defined groups, and next-generation antibody and cell therapies — plus… This week's papers: 1. Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. — New England Journal of Medicine 2026 2. Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer. — Cancer Discovery 2026 3. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (… — The Lancet 2026 4. The changing therapeutic landscape of small-cell lung cancer. — The Lancet 2026 5. Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CU… — Journal of Clinical Oncology 2026 6. Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myelom… — The Lancet Oncology 2026 7. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRC… — The Lancet Oncology 2026 8. Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial. — JAMA Oncology 2026 9. Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial. — JAMA Oncology 2026 10. An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentr… — The Lancet Oncology 2026 Listen at https://audioscholar.cc/episode/th6q99xcfv

See All (25)

About

Oncology — a weekly podcast briefing of the most significant peer-reviewed oncology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

Information